TC BioPharm (Holdings)の空売り状況は、投資家がTC BioPharm (Holdings)の株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

TC BioPharm (Holdings) (NASDAQ:TCBP) 株価情報, 空売り情報

TC BioPharm (Holdings)

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings) PLC

Eneboparatide was well tolerated. After the 24-week randomized treatment period, all patients receive eneboparatide in the ongoing long-term extension period until 52 weeks. Full efficacy and safety data will be analyzed at 52 weeks. Alexion plans to share these data with global health authorities and present them at forthcoming medical meetings.
 &nbsp;

Biotech

Large Cap

News

Health Care

General

The European Union Has Approved AstraZeneca's Imfinzi (Durvalumab) As Monotherapy For Limited-stage Small Cell Lung Cancer Whose Disease Has Not Progressed Following Platinum-based Chemoradiation Therapy

-Wall Street Journal Citing Interview

UBER

WeRide CEO Said Aims To Grow Fleet To Over 5,000 Robotaxis Within Next Three Years; Said To Partner With Uber On Launch Of Robotaxis in Abu Dhabi

Piper Sandler analyst Clarke Jeffries maintains EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) with a Neutral and lowers the price target from $11 to $9.

Price Target

Analyst Ratings

EVCM

Piper Sandler Maintains Neutral on EverCommerce, Lowers Price Target to $9

The primary endpoint is a composite of normalization of albumin-adjusted serum calcium levels and independence from active vitamin D and oral calcium therapy.
Eneboparatide was well tolerated. After the 24-week randomised treatment period, all patients receive eneboparatide in the ongoing long-term extension period until 52 weeks. Full efficacy and safety data will be analysed at 52 weeks. Alexion plans to share these data with global health authorities and present them at forthcoming medical meetings.
 &nbsp;

AstraZeneca Released High-level Results From CALYPSO Phase 3 Trial Showing That Eneboparatide (AZP-3601) Met Its Primary Endpoint With Statistical Significance In Adults With Chronic Hypoparathyroidism At 24 Weeks, Compared To Placebo

Alteogen Will Be Responsible For Clinical And Commercial Supply Of ALT-B4 To AstraZeneca
AstraZeneca will make an upfront payment to Alteogen and additional payments upon achievement of specific development, regulatory and sales-related milestones. Additionally, Alteogen will receive royalties on the sales of the commercialised products.
The transaction does not impact AstraZeneca's financial guidance for 2025. &nbsp;

Contracts

AstraZeneca And Alteogen Have Entered Into An Exclusive License Agreement, AstraZeneca Will Acquire Worldwide Rights To Use ALT-B4 To Develop And Commercialize Subcutaneous Formulations Of Several Oncology Assets

The recent downturn in Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) value has significantly affected the unrealized gains of Strategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), which has made substantial investments in the cryptocurrency.
What Happened: Strategy&#8217;s paper profits have taken a hit and slipped below $9 billion as Bitcoin struggles to break through key resistance levels, as per a report <a href="https://www.tokenpost.com/news/business/14434">by</a> The Tokenpost. The company&#8217;s total Bitcoin holdings are now worth less than before, leading to questions about the viability of its investment approach. In November, <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41874605/michael-saylors-microstrategy-racks-up-over-10b-in-unrealized-profit-as-bitcoin-blows-past-82k'">the firm gained over </a>$10 billion in profit from its Bitcoin investments.
Since 2020, Strategy has been proactively adding Bitcoin to its treasury, buying the asset at various price levels, including near record highs.&nbsp;However, the company&#8217;s holdings have come under pressure due to the recent market downturn. With Bitcoin currently trading below $84,000, Strategy&#8217;s recent acquisitions have not produced the anticipated returns.
This situation has raised concerns about the company&#8217;s method&nbsp;of using new stock offerings&nbsp;to purchase more Bitcoin. Although Bitcoin has shown some recovery, its inability to surpass the critical resistance level of $87,000 keeps Strategy&#8217;s holdings under pressure.
SEE ALSO: <a href="https://www.benzinga.com/general/entertainment/25/03/44319045/jeff-bezos-is-genius-who-helped-benefit-himself-and-the-world-with-amazon-vc-says-the-beneficiary-is-the-consumer">Jeff Bezos Is Genius Who Helped Benefit Himself And The World With Amazon, VC Says: &#8216;The Beneficiary Is The Consumer&#8217;</a>
Why It Matters: The recent dip in Bitcoin&#8217;s price <a href="https://www.benzinga.com/25/03/44349226/bitcoin-ethereum-dogecoin-slid-ahead-of-feds-interest-rate-decision-analyst-predicts-8-btc-upside-if-it-breaks-through-this-pattern">comes ahead of</a> the Federal Reserve&#8217;s decision on interest rates. Leading cryptocurrencies experienced a drop as investors anticipated the Fed&#8217;s decision with Bitcoin witnessing a volatile Friday, fluctuating between $85,000 and $82,000. This context adds to the pressure on Strategy&#8217;s Bitcoin holdings and underscores the need for a potential shift in its investment strategy.
Despite the downturn, Strategy&#8217;s co-founder Michael Saylor stays bullish on Bitcoin. In his latest speech at the Bitcoin Policy Institute, Saylor stated that the cryptocurrency is critical to the prosperity of the U.S. and the nation can become the global Bitcoin superpower.
In another post on X, Saylor said, &#8220;Bitcoin is an Orange Dwarf— the brightest object in the financial system— growing stronger, hotter, and denser as it attracts capital.&#8221;
Meanwhile, cryptocurrency analyst Ali Martinez referred to $81,400 as a significant test for Bitcoin, stating that if the price stays above this level, its upward momentum will persist.
MSTR holds a momentum rating of 99.98% and a growth rating of 7.27%, according to&nbsp;<a href="https://www.benzinga.com/report/MSTR" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. The Benzinga Growth metric evaluates a stock&#8217;s historical earnings and revenue expansion across multiple timeframes, prioritizing both long-term trends and recent performance. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44348135/shiba-inus-burn-rate-soars-removing-505-million-tokens-from-circulation">Shiba Inu&#8217;s Burn Rate Soars, Removing 505 Million Tokens From Circulation</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Tech

$BTC

MSTR

Strategy's Unrealized Gains Hit Hard Following Bitcoin's Price Slump

DXC Technology Selected By Parfois To Implement Advanced Data Intelligence Strategy

Piper Sandler analyst Clarke Jeffries reiterates Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) with a Overweight and maintains $7 price target.

Reiteration

RSKD

Piper Sandler Reiterates Overweight on Riskified, Maintains $7 Price Target

ANTE

AirNet Technology Announced The Execution Of A Non-binding Investment Letter Of Intent With LLP STH Corp, A Kazakstan Company

Nokia Has Been Selected By Hetzner To Upgrade Its Data Center And Core Network Infrastructure

Nokia Announced That Worldstream Will Use Nokia's Network Security Technology To Protect Businesses In The Netherlands And Globally Against Large-scale DDOS Attacks

U.S. stocks settled higher on Friday, with the S&amp;P 500 surging more than 2% during the session.
Despite Friday's gains, stocks recorded losses last week. The Dow dipped around 3.1% to record its worst week since March 2023. The S&amp;P 500 dipped more than 2%, recording its fourth straight losing week.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Trevor Walsh
<ul>
<li>Analyst Firm: Citizens Capital Markets</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Reiterated a Market Perform rating on Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) on March 14.</li>
<li>Recent News: On March 15, Rocket Lab USA announced its third Pioneer spacecraft for Varda Space Industries, Inc. is successfully operating on orbit.</li>
</ul>
Analyst: Mark Hughes
<ul>
<li>Analyst Firm: Truist Securities</li>
<li>Ratings Accuracy: 83%</li>
<li>Latest Rating: Maintained a Hold rating on James River Group Holdings, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>) and cut the price target from $6 to $5 on March 11. This analyst sees around 25% surge in the stock.</li>
<li>Recent News: On March 4, James River Group reported worse-than-expected fourth-quarter EPS results.</li>
</ul>
Analyst: Rob Owens 
<ul>
<li>Analyst Firm: Piper Sandler</li>
<li>Ratings Accuracy: 82%</li>
<li>Latest Rating: Maintained an Overweight rating on SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) and cut the price target from $32 to $28 on March 13. This analyst sees around 52% upside in the stock.</li>
<li>Recent News: On March 12, SentinelOne reported fourth-quarter revenue of $225.5 million, beating the consensus estimate of $222.25 million, according to Benzinga Pro.</li>
</ul>
Analyst: Aaron Rakers
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 82%</li>
<li>Latest Rating: Maintained an Overweight rating on Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) and cut the price target from $140 to $130 on March 13. This analyst sees around 29% upside in the stock.</li>
<li>Recent News: On March 5, Micron named Mark Liu and Christie Simons to Board of Directors.</li>
</ul>
Analyst: Alexander Paris
<ul>
<li>Analyst Firm: Barrington Research</li>
<li>Ratings Accuracy: 81%</li>
<li>Latest Rating: Maintained an Outperform rating on HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a price target of $112 on March 14. This analyst sees around 15% upside in the stock.</li>
<li>Recent News: On Feb. 18, HealthEquity affirmed guidance for fiscal 2025 and 2026.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44326690/top-3-materials-stocks-that-may-collapse-in-march">Top 3 Materials Stocks That May Collapse In March</a></li>
</ul>

Earnings

Pre-Market Outlook

Trading Ideas

JRVR

RKLB

5 Stock Picks Last Week From Wall Street's Most Accurate Analysts

Full Year&nbsp;of 2024 Financial Highlights
<ul>
<li>Net revenues from sales of batteries were $136.59 million, an increase of 2.7% from $132.99 million in the same period of 2023.
<ul>
<li>Net revenues from batteries used in light electric vehicles were $10.32 million, an increase of 84% from $5.61 million in the same period of 2023.</li>
<li>Net revenues from batteries used in electric vehicles were $1.68 million, a decrease of 41.67% from $2.88 million in the same period of 2023.</li>
<li>Net revenues from residential energy supply &amp; uninterruptible supplies were $124.59 million, an increase of 0.1% from $124.5 million in the same period of 2023.</li>
</ul>
</li>
<li>Gross margin for the battery business was 31.5%, an increase of 7.7 percentage points from 23.8% in the same period of 2023.</li>
<li>Net income from the battery business was $19.43 million, an increase of 39.08% from $13.97 million in the same period of 2023.</li>
</ul>

CBAT

CBAK Energy Tech 2024 GAAP EPS $0.13 Up From $(0.03) YoY, Revenue $176.614M Down From $204.438M YoY

Former Nissan Motor Co. chief Carlos Ghosn claims his 18 years of work at the struggling Japanese automaker have been &#8220;wasted&#8221; while suggesting Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk could potentially fix the company&#8217;s mounting problems.
What Happened: Speaking from his home in Beirut, Lebanon, the fugitive former executive told Shukan Post that Nissan&#8217;s current leadership lacks &#8220;vision, decision, clarity, judgment, insight&#8221; following his dramatic 2018 arrest and subsequent escape from Japan.
&#8220;All the work I and my team did there over 18 years is wasted,&#8221; Ghosn said in the interview, as Nissan continues to struggle financially, having burned through ¥506 billion ($6.6 billion) in the first nine months of the fiscal year despite holding ¥1.2 trillion ($15.65 billion) in net cash, <a href="https://japantoday.com/category/features/kuchikomi/ghosn-says-all-his-work-wasted-at-nissan-says-musk-could-fix-automaker">reported</a> Japan Today
When asked what he would do if still in charge, Ghosn mentioned &#8220;My friend Elon Musk,&#8221; suggesting the world&#8217;s richest man could help turn around the automaker&#8217;s fortunes.
Nissan did not immediately respond to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga</a>'s request for comment.
See Also: <a href="https://www.benzinga.com/markets/equities/25/03/44350873/nvidia-faces-new-ai-challenge-as-chinese-start-up-unveils-framework-to-cut-reliance-on-its-gpus">Nvidia Faces New AI Challenge As Chinese Start-Up Unveils Framework To Cut Reliance On Its GPUs</a>
Why It Matters: The comments come as Honda Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) reportedly remains open to reviving merger talks with Nissan that could create the world&#8217;s <a href="https://in.benzinga.com/markets/equities/25/02/43771894/honda-open-to-reviving-nissan-merger-talks-if-ceo-uchida-steps-down-creating-fourth-largest-global-automaker">fourth-largest automaker</a>, but only if current Nissan CEO Makoto Uchida steps down. Previous negotiations collapsed when Honda demanded full ownership rather than an equal partnership.
Meanwhile, Renault (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RNLSY#OTC">RNLSY</a>), which owns 36% of Nissan, is exploring options to sell its stake at a premium, while other potential investors including Foxconn, KKR &amp; Co. and U.S. automakers evaluate opportunities.
Ghosn, who rescued Nissan from near bankruptcy in 1999 by cutting 21,000 jobs and closing five plants, maintains he was a victim of Japan&#8217;s &#8220;corrupt&#8221; justice system. After spending 108 days in detention following financial misconduct charges, he escaped Japan in December 2019 hidden inside a box on a private jet.
&#8220;I have no regrets regarding my escape,&#8221; Ghosn told Shukan Post. &#8220;The treatment I received at the hands of prosecutors was cruel, inhuman and unfair.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44349818/warren-buffett-dumped-nearly-70-of-apple-shares-but-its-price-to-sales-ratio-remains-elevated-at-8-2x-warns-this-market-analyst">Warren Buffett Dumped Nearly 70% Of Apple Shares, But Its Price-To-Sales Ratio Remains Elevated At 8.2x, Warns This Market Analyst</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

RNLSY

TSLA

Elon Musk As Nissan's Fix? Carlos Ghosn Says Automaker Lacks 'Vision, Decision, Clarity, Judgment, Insight'

<h3>Companies Reporting Before The Bell</h3>
• Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) is expected to report quarterly earnings at $1.68 per share on revenue of $597.66 million. 
• LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $23.55 million. 
• NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is likely to report earnings for its fourth quarter. 
• CBAK Energy Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAT#NASDAQ">CBAT</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $50.11 million. 
• Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $20.21 million. 
• NextPlat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>) is projected to report earnings for its fourth quarter. 
• Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) is projected to report quarterly earnings at $2.07 per share on revenue of $1.81 billion. 
• Inspired Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSE#NASDAQ">INSE</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $81.72 million. 
• Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) is projected to report earnings for its fourth quarter. 
• Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $5.74 million. 
• Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) is likely to report earnings for its fourth quarter. 
• Townsquare Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSQ#NYSE">TSQ</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $116.41 million. 
<h3>Companies Reporting After The Bell</h3>
• DiaMedica Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) is likely to report earnings for its fourth quarter. 
• Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) is expected to report earnings for its fourth quarter. 
• High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) is estimated to report earnings for its first quarter. 
• Eastman Kodak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) is expected to report earnings for its fourth quarter. 
• Health In Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIT#NASDAQ">HIT</a>) is estimated to report earnings for its first quarter. 
• Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) is likely to report earnings for its fourth quarter. 
• Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $24.03 million. 
• Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) is expected to report quarterly loss at $0.11 per share on revenue of $42.51 million. 
• Natural Gas Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>) is projected to report quarterly earnings at $0.25 per share on revenue of $40.84 million. 
• Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) is projected to report quarterly loss at $0.14 per share on revenue of $3.77 million. 
• FinVolution Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) is likely to report earnings for its fourth quarter. 
• FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) is expected to report quarterly loss at $0.20 per share on revenue of $24.91 million. 
• Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) is likely to report earnings for its fourth quarter. 
• Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is likely to report quarterly loss at $1.25 per share on revenue of $21.61 million. 
• B. Riley Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) is estimated to report earnings for its fourth quarter. 
• Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $33.60 million. 
• RF Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RFIL#NASDAQ">RFIL</a>) is expected to report earnings for its first quarter. 
• Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $59.09 million. 
• Hallador Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) is likely to report quarterly loss at $0.05 per share on revenue of $102.46 million. 
• Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $46.55 million. 
• Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $244.87 million. 
• Lithium Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAR#NYSE">LAR</a>) is expected to report quarterly loss at $0.04 per share on revenue of $48.40 million. 
• Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) is projected to report quarterly loss at $0.22 per share on revenue of $35.55 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPS

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLTE

CODA

CWCO

DMAC

FGEN

FINV

GETY

HITI

HNRG

HROW

HYPR

INSE

KODK

LNZA

LPRO

NRGV

NRXP

NXPL

QFIN

QTRX

RBOT

RFIL

RILY

SAIC

SGMO

SNDA

Earnings Scheduled For March 17, 2025

The S&amp;P 500 index jumped over 2% on Friday, after a fall into the correction zone on Thursday last week, whereas the Nasdaq continues to be in the correction territory. While technical analysis points toward bearish trends, this analyst says that investors can start looking for buy signals.
What Happened: As of Friday, the S&amp;P 500 index was 8.27% down from its 52-week high, which followed a bounce from Thursday&#8217;s 10.18% drawdown. Similarly, Nasdaq 100 was 11.33% lower from its 52-week high as of Friday.
According to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> and <a href="https://www.benzinga.com/report/SPY">Edge Rankings</a>, the technical analysis of the exchange-traded fund tracking the S&amp;P 500 index, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) were flashing warning signals.
Despite that Jay Kaeppel, the senior market analyst at SentimenTrader via his Panic/Euphoria analysis model showed that the S&amp;P 500&#8217;s decline was still not flashing a buy signal. However, from this point, investors could "Start looking for a buy signal".
According to the chart shared by him, when the Panic/Euphoria line falls below the Excessive Pessimism level, investors could expect a bounce back with an average of over 7% return after two months and 28% returns after a year. But, this follows a series of red dots representing that investors should take a backseat.
Hence, as his model shows the presence of only one red dot, Kaeppel doesn&#8217;t forecast a buy yet, but the start of a potentially emerging buy signal.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Is this a "Buy" signal? IMO, no. Is this a "Start looking for a buy signal" signal? IMO, yes. Doesn't mean it will come soon or that things can't get worse as the first "dot" rarely marks the exact bottom (only in 2018). Still, the numbers are what they are. <a href="https://twitter.com/sentimentrader?ref_src=twsrc%5Etfw">@sentimentrader</a> <a href="https://t.co/6Xq1lk9kNj">pic.twitter.com/6Xq1lk9kNj</a>
&mdash; Jay Kaeppel (@jaykaeppel) <a href="https://twitter.com/jaykaeppel/status/1900529743218286779?ref_src=twsrc%5Etfw">March 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/25/03/44350479/warren-buffett-plans-to-sell-his-real-estate-brokerage-but-its-not-a-bet-against-us-home-prices-says-analyst-as-f">Warren Buffett Plans To Sell His Real Estate Brokerage, But It&#8217;s &#8216;Not… A Bet Against US Home Prices,&#8217; Says Analyst As Fed Expects To Keep Rates Unchanged</a>
Why It Matters: SPY fell below its 200-day moving average on Thursday after its longest-ever streak and its technical charts showed that it was below all its short and long-term moving averages. The MACD momentum indicator was negative 11.38, signaling a downtrend in the short-term and its relative strength index of 37.72 was in the neutral zone.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17034721/SPY-tech-chart-1024x576.png" alt="" class="wp-image-826695" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17034721/SPY-tech-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17034721/SPY-tech-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17034721/SPY-tech-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17034721/SPY-tech-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17034721/SPY-tech-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Similarly, the Edge Rankings showed that SPY had a poor price trend in short, medium, and long term, with a momentum ranking of 64.34 percentile.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/report/SPY"><img loading="lazy" decoding="async" width="799" height="138" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17034654/Edge-rankings.png" alt="" class="wp-image-826692" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17034654/Edge-rankings.png 799w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17034654/Edge-rankings-300x52.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17034654/Edge-rankings-768x133.png 768w" sizes="(max-width: 799px) 100vw, 799px" /></a></figure>
Price Action: The SPY and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose on Friday. The SPY advanced 2.07% to $562.81, and the QQQ also jumped 2.42% to $479.66, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44298732/nvidia-valuation-drops-after-2025-rout-ai-chipmakers-price-declines-41-from-its-peak-when-chatgpt-was-launched" target="_blank" rel="noreferrer noopener">Nvidia Valuation Drops After 2025 Rout: Chipmaker's Price Declines 41% From Its Peak When ChatGPT Was Launched</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

Market Summary

S&P 500 Price Trend Flashes Warning Signals But This Expert Says 'Start Looking For A Buy Signal' After Last Week's Drawdown

Guidance

Niu Technologies Sees FY25 Sales Volume Of 1.3M - 1.6M Units

Niu Technologies Sees Q1 Revenue Of RMB 631M - RMB 707M

Niu Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) reported quarterly losses of $(0.06) per share. This is a 73.91 percent increase over losses of $(0.23) per share from the same period last year. The company reported $112.23 million in sales this quarter. This is a 66.46 percent increase over sales of $67.42 million the same period last year.

Niu Technologies Q4 EPS $(0.06) Up From $(0.23) YoY, Sales $112.23M Up From $67.42M YoY

A new artificial intelligence framework developed by a Chinese start-up could reduce reliance on Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips for AI model inference, marking the latest effort by Chinese tech companies to achieve technological self-sufficiency amid U.S. export restrictions.
What Happened: Qingcheng.AI, founded by Tsinghua University professor Zhai Jidong, unveiled &#8220;Chitu&#8221; &#8211; a high-performance inference framework for large language models that can operate on Chinese-made chips, <a href="https://www.scmp.com/tech/tech-war/article/3302516/chip-war-chinese-start-aims-break-nvidias-grip-ai-new-model-framework?module=perpetual_scroll_0&amp;pgtype=article">reported</a> South China Morning Post.
The open-source framework directly challenges Nvidia&#8217;s dominance in supporting advanced AI models like DeepSeek-R1, according to a joint statement released Friday.
When tested with DeepSeek-R1 using Nvidia&#8217;s A800 GPUs, Chitu achieved a 315% increase in model inference speed while reducing GPU usage by 50% compared to foreign frameworks, the company claimed.
The development comes amid heightened AI competition in China following DeepSeek&#8217;s breakthrough in January, which demonstrated high-performance models at significantly lower costs than U.S. competitors. DeepSeek&#8217;s success triggered a selloff in U.S. tech stocks, with Nvidia <a href="https://in.benzinga.com/markets/equities/25/02/43590545/nvidias-600-billion-sell-off-a-buying-opportunity-or-the-start-of-ai-market-disruption">losing $593 billion in market value</a> as investors feared increased competition.
See Also: <a href="https://www.benzinga.com/markets/equities/25/03/44350195/ross-gerber-shares-peaceful-display-of-distaste-for-elon-musk-in-santa-monica-his-9-year-old-observes-glad-we-dont-have-a-tesla">Ross Gerber Shares &#8216;Peaceful Display Of Distaste For Elon Musk&#8217; In Santa Monica, His 9-Year Old Observes, &#8216;Glad We Don&#8217;t Have A Tesla&#8217;</a>
Why It Matters: Chinese tech giants are rapidly entering the race. Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) on Sunday unveiled ERNIE X1, <a href="https://in.benzinga.com/25/03/44349635/baidu-says-its-new-ai-is-smarter-than-deepseeks-and-costs-half-as-much-excellent-multimodal-understanding-ability">claiming performance comparable</a> to DeepSeek-R1 at half the price. Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) recently launched R1-Omni, an emotion-reading <a href="https://www.benzinga.com/markets/equities/25/03/44296725/alibaba-launches-ai-that-reads-emotions-to-rival-openai-but-shares-falls-on-hong-kong-exchange-despite-joe-tsais-10-trillion-market-outlook">AI model available for free</a>.
These initiatives reflect China&#8217;s broader push for technological independence after Washington banned sales of Nvidia&#8217;s advanced H100 and H800 chips to China-based clients. Backed by Beijing&#8217;s municipal AI fund, Qingcheng.AI has partnered with top Chinese GPU manufacturers including Moore Threads, Enflame and Iluvatar CoreX.
The AI surge has reignited investor interest in Chinese tech, potentially reversing three years of venture capital decline. &#8220;People are rushing just to find the next DeepSeek,&#8221; said Annabelle Yu Long, founding partner of BAI Capital, as the Chinese government <a href="https://in.benzinga.com/markets/25/03/44268864/chinese-investors-rushing-to-find-the-next-deepseek-says-vc-as-ai-boom-fuels-investment-surge-after-nvidia-selloff">prepares a fund expected</a> to mobilize 1 trillion yuan ($137.7 billion) for tech investment.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44348859/trump-says-he-was-little-bit-sarcastic-when-he-said-he-would-end-the-russia-ukraine-war-in-a-day-what-i-really-mean-is" target="_blank" rel="noreferrer noopener">Trump Says He Was ‘Little Bit Sarcastic&#8217; When He Said He Would End The Russia-Ukraine War In A Day: ‘What I Really Mean Is…&#8217;</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Startups

BABA

BIDU

NVDA

Nvidia Faces New AI Challenge As Chinese Start-Up Unveils Framework To Cut Reliance On Its GPUs

Press Releases

TCBP Provides Update on Acquisition Strategy and Current Targets

TCBP Trading Continues Unabated on Nasdaq Stock Exchange

Dividends

/C O R R E C T I O N -- TC BioPharm/

TCBP to Present at Sequire Investor Summit 2025

TCBP Announces H5N1 Proof of Concept Studies Intention

TCBP to Implement ADS Ratio Change

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial

TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

Small Cap

TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company

Comments

TC BioPharm (Holdings)

空売り

TC BioPharm (Holdings) (NASDAQ:TCBP) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル